Dr. Joseph M. Tuscano
Claim this profileUniversity of California Davis Comprehensive Cancer Center
Expert in Lymphoma
Studies B-Cell Lymphoma
19 reported clinical trials
37 drugs studied
Area of expertise
1Lymphoma
Global LeaderStage IV
Stage III
13q positive
2B-Cell Lymphoma
Philadelphia chromosome positive
CD19 positive
CD20 positive
Affiliated Hospitals
Clinical Trials Joseph M. Tuscano is currently running
Triple Drug Therapy
for Follicular Lymphoma
This phase II trial studies how well obinutuzumab, ibrutinib, and venetoclax work in treating patients with previously untreated stage II-IV follicular lymphoma. Immunotherapy with obinutuzumab may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Ibrutinib and venetoclax may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving obinutuzumab, ibrutinib, and venetoclax together may work better in treating follicular lymphoma compared to each drug alone.
Recruiting1 award Phase 210 criteria
Loncastuximab Tesirine + Rituximab
for Diffuse Large B-Cell Lymphoma
This phase II trial evaluates whether loncastuximab tesirine and rituximab followed by dose-adjusted doxorubicin, etoposide, vincristine, cyclophosphamide, and prednisone works to treat patients with high risk diffuse large B-cell lymphoma. Loncastuximab tesirine is a monoclonal antibody called loncastuximab, linked to a drug called tesirine. It is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as CD19 receptors, and delivers tesirine to kill them. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Chemotherapy drugs such as doxorubicin, vincristine, and cyclophosphamide work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill cancer cells. Prednisone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Giving loncastuximab tesirine and rituximab in combination with dose-adjusted doxorubicin, etoposide, vincristine, cyclophosphamide, and prednisone may be more effective at treating high risk diffuse large B-cell lymphoma patients than standard treatments.
Recruiting1 award Phase 2
More about Joseph M. Tuscano
Clinical Trial Related5 years of experience running clinical trials · Led 19 trials as a Principal Investigator · 9 Active Clinical TrialsTreatments Joseph M. Tuscano has experience with
- Rituximab
- Lenalidomide
- Obinutuzumab
- Ibrutinib
- Venetoclax
- Brentuximab Vedotin
Breakdown of trials Joseph M. Tuscano has run
Lymphoma
B-Cell Lymphoma
Non-Hodgkin's Lymphoma
Diffuse Large B-Cell Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Joseph M. Tuscano specialize in?
Joseph M. Tuscano focuses on Lymphoma and B-Cell Lymphoma. In particular, much of their work with Lymphoma has involved Stage IV patients, or patients who are Stage III.
Is Joseph M. Tuscano currently recruiting for clinical trials?
Yes, Joseph M. Tuscano is currently recruiting for 9 clinical trials in Sacramento California. If you're interested in participating, you should apply.
Are there any treatments that Joseph M. Tuscano has studied deeply?
Yes, Joseph M. Tuscano has studied treatments such as Rituximab, Lenalidomide, Obinutuzumab.
What is the best way to schedule an appointment with Joseph M. Tuscano?
Apply for one of the trials that Joseph M. Tuscano is conducting.
What is the office address of Joseph M. Tuscano?
The office of Joseph M. Tuscano is located at: University of California Davis Comprehensive Cancer Center, Sacramento, California 95817 United States. This is the address for their practice at the University of California Davis Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.